A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
Status: | Withdrawn |
---|---|
Conditions: | Blood Cancer, Leukemia |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 4/21/2016 |
Start Date: | August 2010 |
End Date: | December 2013 |
The purpose of this study is to determine if the magnetic needle, in combination with
magnetic nanoparticles can accurately identify minimal residual disease in leukemia
patients.
magnetic nanoparticles can accurately identify minimal residual disease in leukemia
patients.
The ability to reliably detect Minimal Residual Disease (MRD) in leukemia patients allows
oncologists to predict patient outcome and to monitor the efficacy of therapy which is
critical to improving care. MRD can be used to identify high risk patients who cannot be
identified by conventional high risk features, a presence of < 0.1% MRD has been shown to be
one of the best predictors of 5-year remission, with 70% of patients with ≥ 0.1% relapsing.
In addition to providing predictions of relapse, MRD has been shown to provide a sensitive
measure of early treatment response, an independent predictor of good outcome. While the
presence of MRD is indicative of patient outcome, the detection of the presence of MRD
provides an opportunity to modify treatment and potentially increase survival. Studies are
currently underway to use MRD detection in modifying chemotherapeutic treatment and timing
of stem cell transplant in leukemia patients. Development of a low cost and easily
accessible MRD detector has the potential to expand the number of patients for which MRD
testing is available. Expansion of the patient population is a necessary step to large scale
testing of MRD detection as both a predictive factor of patient outcome and as a potential
modifier of patient treatment. It is expected that increased MRD testing would lead to
improved prediction of patient outcomes and increased sensitivity of testing of treatment
response. MRD testing in the general patient population could be used to test treatment
response and allow oncologists to modify treatment regiments leading to reduced patient
mortality and improved medical outcomes.
oncologists to predict patient outcome and to monitor the efficacy of therapy which is
critical to improving care. MRD can be used to identify high risk patients who cannot be
identified by conventional high risk features, a presence of < 0.1% MRD has been shown to be
one of the best predictors of 5-year remission, with 70% of patients with ≥ 0.1% relapsing.
In addition to providing predictions of relapse, MRD has been shown to provide a sensitive
measure of early treatment response, an independent predictor of good outcome. While the
presence of MRD is indicative of patient outcome, the detection of the presence of MRD
provides an opportunity to modify treatment and potentially increase survival. Studies are
currently underway to use MRD detection in modifying chemotherapeutic treatment and timing
of stem cell transplant in leukemia patients. Development of a low cost and easily
accessible MRD detector has the potential to expand the number of patients for which MRD
testing is available. Expansion of the patient population is a necessary step to large scale
testing of MRD detection as both a predictive factor of patient outcome and as a potential
modifier of patient treatment. It is expected that increased MRD testing would lead to
improved prediction of patient outcomes and increased sensitivity of testing of treatment
response. MRD testing in the general patient population could be used to test treatment
response and allow oncologists to modify treatment regiments leading to reduced patient
mortality and improved medical outcomes.
Group: Leukemia Patients
Inclusion Criteria:
- Suspected diagnosis of Leukemia
- Requiring bone marrow biopsy for standard care
Exclusion Criteria:
- unable to consent for entrance into the study
Group: Non-leukemia Patients
Inclusion Criteria:
- Requiring bone marrow biopsy for standard care
Exclusion Criteria:
- unable to consent for entrance into the study
- Leukemia diagnosis
We found this trial at
1
site
Click here to add this to my saved trials